HK1076474A1 - Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours - Google Patents

Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Info

Publication number
HK1076474A1
HK1076474A1 HK05108339.8A HK05108339A HK1076474A1 HK 1076474 A1 HK1076474 A1 HK 1076474A1 HK 05108339 A HK05108339 A HK 05108339A HK 1076474 A1 HK1076474 A1 HK 1076474A1
Authority
HK
Hong Kong
Prior art keywords
tumours
fibronectin
conjugates
domain
detection
Prior art date
Application number
HK05108339.8A
Other languages
English (en)
Inventor
Christoph-Stephan Hilger
Dietmar Berndorff
Ludger Dinkelborg
Dieter Moosmayer
Giovanni Neri
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HK1076474A1 publication Critical patent/HK1076474A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK05108339.8A 2002-01-03 2005-09-22 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours HK1076474A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02000315 2002-01-03
US35870202P 2002-02-25 2002-02-25
PCT/EP2003/000009 WO2003055917A2 (en) 2002-01-03 2003-01-02 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Publications (1)

Publication Number Publication Date
HK1076474A1 true HK1076474A1 (en) 2006-01-20

Family

ID=26077560

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05108339.8A HK1076474A1 (en) 2002-01-03 2005-09-22 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours

Country Status (15)

Country Link
US (1) US20040001790A1 (ru)
EP (2) EP2239274A1 (ru)
JP (2) JP2005523887A (ru)
CN (1) CN1612895B (ru)
AU (1) AU2003210149B2 (ru)
BR (1) BR0306715A (ru)
CA (1) CA2468081A1 (ru)
CY (1) CY1110923T1 (ru)
HK (1) HK1076474A1 (ru)
IL (2) IL162201A0 (ru)
MX (1) MXPA04006517A (ru)
NO (1) NO20043246L (ru)
PL (1) PL369371A1 (ru)
RU (1) RU2352582C2 (ru)
WO (1) WO2003055917A2 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
AU1218202A (en) * 2000-09-07 2002-03-22 Schering Ag Receptor in the ED<sub>b</sub> fibronectin domain
EP1483297B1 (en) * 2002-03-11 2009-12-23 Philogen S.p.A. Antibodies derived from anti ed-b l19 and targeting tumor vasculature
EP1514561A1 (en) * 2003-09-10 2005-03-16 Philogen S.p.A. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US20060039863A1 (en) * 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
DE602004009169D1 (de) * 2004-07-22 2007-11-08 Bayer Schering Pharma Ag Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
CA2650953A1 (en) * 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
CA2682851C (en) * 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
EP2036576A1 (en) * 2007-09-17 2009-03-18 Bayer Schering Pharma Aktiengesellschaft ED-B fibronectin as stratification marker for antitumor drugs
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
US9603954B2 (en) 2009-07-22 2017-03-28 Actinium Pharmaceuticals Inc. Methods for generating radioimmunoconjugates
JP5892540B2 (ja) * 2009-12-25 2016-03-23 国立研究開発法人理化学研究所 生体内にて標的組織に指向する放射標識化合物およびその利用
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
CN104215668A (zh) * 2014-08-25 2014-12-17 浙江大学 基于theed纤维阵列的二氧化碳传感器及其制备方法
EP3378947B1 (en) * 2015-11-16 2024-01-24 Hefei Lifeon Pharmaceutical Co. Ltd. Use of ed-b protein in diagnosis of tissue hyperplasia
SG11201903400WA (en) * 2016-10-17 2019-05-30 Pfizer Anti-edb antibodies and antibody-drug conjugates
CN115666645A (zh) * 2020-05-22 2023-01-31 菲洛根股份公司 用于脑瘤治疗的TNFα免疫缀合物疗法
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0486622T3 (da) * 1989-08-09 1999-07-19 Rhomed Inc Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium
WO1993016185A2 (en) * 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
NZ514918A (en) * 1999-04-28 2003-11-28 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting VEGF
EP1259548A1 (en) 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis

Also Published As

Publication number Publication date
IL162201A0 (en) 2005-11-20
NO20043246L (no) 2004-08-02
CY1110923T1 (el) 2015-06-10
EP1461360B1 (en) 2010-08-18
MXPA04006517A (es) 2005-03-31
EP2239274A1 (en) 2010-10-13
IL162201A (en) 2011-04-28
BR0306715A (pt) 2004-12-28
WO2003055917A3 (en) 2003-12-24
RU2352582C2 (ru) 2009-04-20
JP2005523887A (ja) 2005-08-11
CN1612895B (zh) 2010-05-12
WO2003055917A2 (en) 2003-07-10
US20040001790A1 (en) 2004-01-01
CA2468081A1 (en) 2003-07-10
JP4663020B2 (ja) 2011-03-30
AU2003210149B2 (en) 2008-10-09
PL369371A1 (en) 2005-04-18
EP1461360A2 (en) 2004-09-29
CN1612895A (zh) 2005-05-04
RU2004123785A (ru) 2005-08-10
AU2003210149A1 (en) 2003-07-15
JP2009209149A (ja) 2009-09-17

Similar Documents

Publication Publication Date Title
HK1076474A1 (en) Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
AU4243201A (en) Antibody specific for the ed-b domain of fibronectin, conjugates comprising saidantibody, and their use for the detection and treatment of angiogenesis
HUP1600016A2 (en) Antibody molecules having specificity for human tumor necrosis factor alpha and use thereof
EP1816953A4 (en) CANCER DETECTION AND TREATMENT INSTRUMENT
HK1089155A1 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
IL173080A0 (en) Assay for human anti cd20 antibodies and uses therefor
EP1799262A4 (en) ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
EP1591073A4 (en) ULTRASONIC PROBE AND ULTRASONIC DEVICE
EP1814909A4 (en) USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
SG104356A1 (en) Absorbent body and absorbent article having the absorbent body
EP1487492A4 (en) PREVENTION OR TREATMENT OF CANCER USING INTEGRIN ALPHAVBETA3 ANTAGONISTS COMBINED WITH OTHER AGENTS
EP1578380A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
GB0422974D0 (en) Living body information detection and display apparatus
IL180278A0 (en) Fused pyrimidones useful in the treatment and the prevention of cancer
EP1913954A4 (en) AGENTS AND METHODS BASED ON THE USE OF THE FIBRONECTIN EDA DOMAIN
EP1587837A3 (en) Prostate cancer diagnosis and treatment
HK1043348A1 (en) Brush-writing instruments for health and therapy
AU2003227148A8 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
ZA200503618B (en) Single domain antibodies directed against Tumour Necrosis Factor-alpha and uses therefor
AU2003215381A8 (en) Egfrviii specific monoclonal antibody and egfrviii ribozymes and use to detect, treat or prevent egfrviii associated cancer
GB2400176B (en) Ultrasound probe and application thereof
PL371202A1 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
SI1639013T1 (sl) Pan-kir2dl nk-receptorska protitelesca in njihova uporaba pri diagnosticiranju in terapiji

Legal Events

Date Code Title Description
PS Patent surrendered
PS Patent surrendered